Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $27.6 million, up from $16 million in Q3 2024, primarily due to a $25 million milestone from Janssen and $1 million in royalties from Jazz Pharmaceuticals and BeiGene [9][10]. - Overall operating expenses decreased slightly to $49.7 million in Q3 2025 from $50.2 million in Q3 2024, a reduction of 1% [10]. - Net loss improved to $19.6 million in Q3 2025 compared to a net loss of $29.9 million in Q3 2024, attributed to increased revenue [10][11]. - Cash, cash equivalents, and marketable securities totaled $299.4 million as of September 30, 2025, down from $324.2 million at the end of 2024 [11]. Business Line Data and Key Metrics Changes - The company recognized a $25 million development milestone from Jazz Pharmaceuticals related to the clinical progress of pacritimab, contributing significantly to revenue [6][9]. - Royalty revenues of $1 million were earned based on Ziihera net product sales by Jazz and BeiGene [8]. Market Data and Key Metrics Changes - The company continues to see strong momentum in its partnered programs, with Jazz presenting positive trial data at ESMO [5][6]. - The first patient has been dosed in the phase one clinical trial of ZW251, targeting GPC3 in hepatocellular carcinoma, indicating ongoing clinical development [4][17]. Company Strategy and Development Direction - The company aims to leverage partnerships to accelerate development and maintain control over R&D innovations while de-risking clinical developments [25][27]. - The focus remains on advancing programs with clear differentiation and strong scientific rationale, utilizing partnerships to offset development risks [27]. - The company is committed to disciplined capital allocation to drive sustainable long-term returns [9][25]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's outlook, citing the strength of the pipeline and the successful execution of clinical trials [8][11]. - The company anticipates that existing cash resources, combined with expected regulatory milestones, will fund operations into the second half of 2027 [11]. Other Important Information - The company completed share repurchases of $22.7 million under its previously authorized program, reflecting confidence in its outlook [8]. - The decision to discontinue the development of ZW171 was made to prioritize programs with clearer paths to patient benefit [20][21]. Q&A Session Summary Question: Thoughts on the update in the PFS analysis for Horizon GEA 01 - Management aligned with Jazz's regulatory strategy regarding the readout of Horizon GEA 01 and did not provide additional comments [30]. Question: Implications of ZW191 data for GPC3 and potential development strategies - Management expressed intrigue regarding the GPC3 construct and emphasized the importance of safety in the hepatocellular carcinoma population [31][33]. Question: Insights on GPC3 payload and preclinical efficacy expectations - Management noted that while topo1 is not standard for liver cancer, there is precedent for its use, and they believe their ADC can deliver effective treatment [38][44]. Question: Confidence in GPC3 activity in the post-IO setting - Management indicated that GPC3 expression levels are not expected to be modulated by IO treatment, supporting their development plan [60][62]. Question: Expectations on durability for ZW191 and potential for partnerships - Management found early data from ZW191 encouraging and indicated ongoing discussions with potential partners [70][71]. Question: Correlation between H-score and PS2 plus scoring methodologies - Management confirmed that H-score is a validated method for evaluating expression levels and correlates well with PS2 plus scores [81][84].

3Q 2025 Results Conference Call and Webcast November 6, 2025 Nasdaq: ZYME | zymeworks.com Legal Disclaimer This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation and the accompanying oral commentary include, but are no ...

Financial Data and Key Metrics Changes - The company has approximately $500 million left in regulatory milestones and about $860 million in commercial milestones, with royalties ranging from 10% to 20% based on net sales [10][11][12] Business Line Data and Key Metrics Changes - The zanidatamab program is a significant focus, with upcoming Phase 3 study readouts expected in Q4, which could drive value for the company [6][10] - ZW171 has been discontinued due to on-target, off-tumor toxicity, reflecting the company's disciplined approach to capital allocation [14][16][17] Market Data and Key Metrics Changes - The competitive landscape for zanidatamab includes potential opportunities in breast cancer, with Jazz Pharmaceuticals exploring this area [11][12] - ZW191 is positioned as a strong contender in the folate receptor alpha ADC space, with a focus on differentiating its product through superior internalization and potency [20][21][22] Company Strategy and Development Direction - The company emphasizes a disciplined approach to capital allocation and decision-making regarding its pipeline programs, focusing on those with the highest potential for patient benefit [14][16] - The strategy includes exploring partnerships for various programs, particularly ZW191, to enhance development and market reach [30][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data readouts and the potential for zanidatamab to capture significant market value, estimating a valuation of over $2 billion [12][13][45] - The company is preparing for multiple catalysts over the next 12 to 18 months, including clinical studies for ZW251 and ZW209 [45] Other Important Information - The ZW209 program, utilizing a tri-TCE platform, is expected to enter clinical trials in the first half of 2026, showcasing the company's commitment to advancing its innovative pipeline [34][45] - The company is also exploring early-stage pipeline opportunities, including novel targets and ADCs, to leverage its protein engineering capabilities [33][34] Q&A Session Summary Question: What is the significance of the upcoming zanidatamab readout? - The readout is expected to provide clarity on the differentiation of zanidatamab in the competitive landscape, particularly in gastroesophageal adenocarcinoma [6][7] Question: What are the financial implications of the zanidatamab program? - The company has significant regulatory and commercial milestones associated with zanidatamab, which could lead to substantial revenue through royalties and milestone payments [10][11] Question: What led to the discontinuation of ZW171? - The decision was based on a lack of efficacy and on-target, off-tumor toxicity, demonstrating the company's commitment to prudent capital allocation [14][16][17] Question: How does Zymeworks differentiate its ADCs? - The company focuses on the holistic design of ADCs, ensuring that the antibody is optimized for internalization and payload delivery, which sets it apart from competitors [20][21][22] Question: What are the next steps for ZW191? - The company is considering partnerships for ZW191 and exploring various tumor types for clinical trials, including ovarian and endometrial cancers [30][39]

Financial Data and Key Metrics Changes - Total revenue increased to $48.7 million in Q2 2025 from $19.2 million in Q2 2024, primarily due to a $20 million milestone from B1 and recognition of $80.3 million in deferred revenue [15][16] - Operating expenses decreased by 20% to $49.4 million in Q2 2025 from $62.1 million in Q2 2024, mainly due to a prior year impairment charge [17] - Net income was $2.3 million for Q2 2025, compared to a net loss of $37.7 million in Q2 2024 [17][18] - Cash resources increased to $333.4 million as of June 30, 2025, from $124.2 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - The company has three product candidates in active Phase I trials in 2025, with two additional candidates expected to enter the clinic in 2026 [7][8] - Zanadatumab showed a median progression-free survival of 15.2 months and overall survival of 36.5 months in a study involving HER2 positive tumors [9][10] - The company recognized a $7.5 million option exercise payment related to a licensing agreement with BMS [14] Market Data and Key Metrics Changes - Conditional regulatory approvals for zanadatumab in China and Europe are expected to increase international patient access and potential future royalties [10][13] - The company anticipates an increase in royalty revenues from zanadatumab's international approvals for biliary tract cancer [13] Company Strategy and Development Direction - The company aims to leverage its proprietary technology platforms and strategic partnerships to enhance asset value and deliver long-term returns for shareholders [44][46] - The focus is on advancing a wholly owned pipeline of differentiated antibody drug conjugates and multi-specific antibodies across various therapeutic areas [46][48] - The company is committed to maintaining a science-first approach while exploring partnerships to share risk and resources [48][49] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of capital discipline and clarity in strategy to drive long-term value [44][51] - The company is focused on maximizing cash flow streams from royalties and other healthcare assets while maintaining flexibility in operations [51][52] - Anticipated growth in royalty and milestone income is not expected to trigger an automatic increase in operational expenditures [51] Other Important Information - The company presented data on its novel IL-4, IL-33 bispecific antibody for COPD at a recent conference, highlighting its potential in treating respiratory diseases [36][38] - The IND clearance for ZW251, targeting hepatocellular carcinoma, is seen as a significant advancement in the company's pipeline [28][29] Q&A Session Summary Question: Will PDL1 status be broken out for the triplet for arm C in the top line? - The inclusion of data in a top line press release will be determined by Jazz and B1, the sponsors of the studies [56][57] Question: How much of the ZANI $525 million regulatory milestone is weighted towards GEA versus other indications? - There is $500 million left in development milestones with Jazz, but no specific guidance on allocation has been provided [57] Question: How does ZW191 compare to other topoisomerase-based ADCs? - The company aims to create a differentiated asset with a novel mechanism and tolerability profile, which could allow for combinations with other treatments [60][63] Question: What is the approach for evaluating ZW251 in liver cancer patients? - The company will systematically study the tolerability and efficacy of ZW251 in appropriate patient subsets, considering liver impairment [68][69] Question: When can data from the Phase I trial of ZW191 be expected? - Initial data is anticipated to be shared at peer-reviewed meetings in 2025 or 2026, depending on abstract acceptance [74] Question: What is known about the expression of alpha in non-small cell lung cancer? - Analysis shows a subset of non-small cell lung cancer patients with BOLT receptor expression, encouraging further evaluation in this indication [78]

Financial Performance & Partnerships - Recognized approximately $75 million in 2025, including around $45 million from partnership-related cash milestones and option exercise fees, which significantly reduced net operating cash burn in the first half of 2025 compared to the first half of 2024[12] - Milestone, option exercise, and related deferred revenue of $45.8 million recognized in 2Q 2025 from BeOne and BMS[16, 17] - Potential future milestone payments from existing partnerships could reach up to $6.1278 billion, with royalty rates varying from low single-digit percentages to 20% depending on the partner and therapeutic indication[13] - Cash, cash equivalents, and marketable securities totaled $324.2 million in 2Q 2025, an increase of $9.2 million year-to-date, benefiting from milestone revenues and favorable working capital movements[16, 17] Clinical Development Updates - Investigational New Drug (IND) application cleared for ZW251, with first-in-human studies planned to start in 2025[11, 12, 47] - Phase 2 trial initiated to evaluate zanidatamab in HER2+ neoadjuvant and adjuvant breast cancer[12] - Bristol Myers Squibb collaboration progresses with a $7.5 million option exercise payment to Zymeworks[12] - ZW171: Global Phase 1 study in MSLN-Expressing Solid Tumors (NCT06523803) is an open-label, FIH, dose-escalation study (N~160)[19] - ZW191: Global Phase 1 Study in FRα-Expressing Solid Tumors (NCT06555744) is an open-label, FIH, dose-escalation study (N~145)[24] Zanidatamab Regulatory & Clinical Progress - NMPA granted BeOne conditional approval of zanidatamab in China for BTC, resulting in a $20 million payment to Zymeworks[12] - EMA granted conditional marketing approval of zanidatamab in Europe for BTC, expanding patient access and potential future royalties payable to Zymeworks[12, 47] - Jazz presented encouraging overall survival (OS) data for zanidatamab in 1L HER2+ GEA at the ASCO Annual Congress, showing a median OS of 36.5 months[12]

Core Insights - Zymeworks Inc. reported financial results for Q2 2025, highlighting significant revenue growth and advancements in its clinical pipeline, particularly with its lead product zanidatamab [1][16]. Financial Performance - Total revenue for Q2 2025 was $48.7 million, a substantial increase from $19.2 million in Q2 2024, driven by milestone payments and deferred revenue recognition [16]. - Research and Development (R&D) expenses rose to $34.4 million in Q2 2025 from $29.2 million in Q2 2024, reflecting increased investment in various clinical programs [16]. - The company achieved a net income of $2.3 million in Q2 2025, a significant turnaround from a net loss of $37.7 million in Q2 2024 [16][21]. Clinical Developments - Zymeworks has three product candidates expected to enter active Phase 1 trials in the second half of 2025, with two additional candidates on track for 2026 [2]. - The IND application for ZW251 was cleared by the FDA, with first-in-human studies planned for 2025 [3][7]. - Zanidatamab has shown promising results in clinical trials, with a median progression-free survival of 15.2 months and overall survival of 36.5 months in patients with HER2-positive gastroesophageal adenocarcinoma [9][10]. Strategic Partnerships - The company has established strategic partnerships that have validated its Azymetric platform, generating meaningful revenue and supporting clinical development [2]. - Zymeworks recognized $20 million in milestone revenue from BeOne Medicines related to the conditional approval of zanidatamab in China [10]. - The collaboration with Jazz Pharmaceuticals for zanidatamab is expected to enhance future royalties, with the European Commission granting conditional marketing authorization for the treatment of HER2-positive biliary tract cancer [11]. Cash Position - As of June 30, 2025, Zymeworks had cash resources of $333.4 million, providing a projected cash runway into the second half of 2027 [3][16].

Core Viewpoint - Zymeworks Inc. is advancing its clinical-stage pipeline with the presentation of new preclinical data for ZW1528, a bispecific molecule targeting IL-4Rα and IL-33, aimed at treating respiratory inflammation, particularly chronic obstructive pulmonary disease (COPD) [1][2]. Group 1: Product Development - ZW1528 demonstrates high affinity binding to IL-4Rα and IL-33, effectively blocking IL-4, IL-13, and IL-33 signaling pathways, which are critical in respiratory inflammation [5][6]. - The bispecific design of ZW1528 shows promising manufacturability and stability, supporting high dosing concentrations and subcutaneous administration [5][7]. - Zymeworks is also developing ZW1572, another bispecific inhibitor targeting IL-4Rα and IL-31 for atopic dermatitis, as part of its expanding IL-4Rα program portfolio [3][5]. Group 2: Preclinical Data and Findings - Preclinical data presented at the ATS conference indicate that ZW1528 can suppress both Type 2 and non-Type 2 immune responses in primary human immune cells from COPD patients [6][7]. - In vivo studies in murine models of lung inflammation show efficacy for ZW1528, with extended pharmacokinetics observed in rodent and non-human primate models [6][7]. - The bispecific antibody's blockade of cytokine-driven activation in human epithelial cells is superior to that achieved with monoclonal antibodies targeting either IL-4Rα or IL-33 [7]. Group 3: Company Overview - Zymeworks is a global biotechnology company focused on developing multifunctional biotherapeutics for difficult-to-treat conditions, including cancer and autoimmune diseases [8]. - The company has a robust pipeline of product candidates and has entered into strategic partnerships to enhance its therapeutic platforms [8].

Pipeline and Technology - Zymeworks has a differentiated pipeline of multifunctional therapeutics targeting solid tumor oncology and autoimmune & inflammatory diseases [8] - The company's ADC technologies combine antibodies with potent payloads for targeted delivery [7] - MSAT technology enhances therapy precision and efficacy, targeting complex disease mechanisms [7] - Zymeworks is advancing next-generation T cell engagers to overcome biological challenges [35] Zanidatamab and Partnerships - Zanidatamab has a potential peak sales of over $2 billion [22] - Zymeworks has a licensing agreement with Jazz Pharmaceuticals, eligible for up to $500 million in regulatory milestones and $862.5 million in commercial milestones [25] - Zymeworks has a licensing agreement with BeiGene, eligible for up to $164 million in development and commercial milestones [25] - Royalties from Jazz are tiered between 10-20%, and from BeiGene, from the high single digits to 19.5% [25] Financials and Milestones - Zymeworks has approximately $321.6 million in cash resources [7] - The company anticipates potential regulatory decisions in the EU and China for zanidatamab in 2L BTC in 2025 [167] - Zymeworks expects an IND submission for ZW251 (GPC3) by mid-2025 [167]

Core Insights - Zymeworks Inc. reported financial results for Q1 2025, highlighting a significant increase in revenue and ongoing advancements in its clinical pipeline [1][15][20] Recent Developments - The appointment of Dr. Sabeen Mekan as Senior Vice President of Clinical Development is expected to enhance Zymeworks' oncology portfolio and regulatory strategy [3] - Six posters were presented at the AACR annual meeting, showcasing progress in the company's T cell engager and antibody-drug conjugate platforms [4][5] Financial Performance - Revenue for Q1 2025 was $27.1 million, a substantial increase from $10.0 million in Q1 2024, driven by milestone revenues from GSK and Daiichi Sankyo [15] - Research and development expenses rose to $35.7 million in Q1 2025 from $32.0 million in Q1 2024, primarily due to increased activities related to ZW251 and ZW209 [16] - The net loss for Q1 2025 was $22.6 million, down from $31.7 million in the same period last year, attributed to higher revenues [20] Cash Position - As of March 31, 2025, Zymeworks had $321.6 million in cash resources, expected to fund operations into the second half of 2027 [21] Pipeline and Collaborations - Zymeworks is advancing multiple clinical candidates, including ZW171 and ZW191, with an investigational new drug application for ZW251 planned by mid-2025 [22] - The company has strategic partnerships with BeiGene and Jazz Pharmaceuticals for the development and commercialization of zanidatamab [22][8]

Financial Data and Key Metrics Changes - Zymeworks reported a net loss of $122.7 million for the year ended December 31, 2024, compared to a net loss of $118.7 million in 2023, primarily due to a $17.3 million noncash impairment charge [14][16] - Revenue for 2024 was $76.3 million, slightly up from $76 million in 2023, including $25 million of milestone revenue from Jazz related to the FDA approval of Ziihera [14][15] - Operating expenses were $213.4 million for 2024, a slight decrease from $214.1 million in 2023, reflecting lower research and development expenses [15][16] Business Line Data and Key Metrics Changes - The company earned over $45 million from partnerships in the past year, with significant contributions from Jazz and BeiGene [10][12] - Ziihera achieved net product sales of $1.1 million in Q4 2024 following its launch, contributing to the company's revenue [11] Market Data and Key Metrics Changes - Zymeworks had approximately $324.2 million in cash resources as of December 31, 2024, down from $456.3 million in 2023, providing a cash runway into the second half of 2027 [21][22] Company Strategy and Development Direction - The company is focused on advancing its next-generation therapeutics, particularly in autoimmune and inflammatory diseases, as well as hematological oncology [9][12] - Zymeworks aims to leverage its innovative platforms to address emerging therapeutic challenges and expand its collaborations [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ZW251 for hepatocellular carcinoma and emphasized the importance of accelerating its clinical studies [46][47] - The company anticipates significant milestones in 2025, including top-line data from the HERIZON-GEA-01 study of zanidatamab [50] Other Important Information - The appointment of Oleg Nodelman to the Board reflects the growth of EcoR1's shareholding and confidence in Zymeworks' potential [48] - The company is exploring the potential of multi-payload ADCs and is investigating additional payloads for its products [120] Q&A Session Summary Question: On ZW251, will there be urgency to initiate combination cohorts? - Management confirmed that they are interested in early signs of tumor activity and will study ZW251 in both dose escalation and expansion cohorts [54][56] Question: What prompted the prioritization of ZW251 over ZW220? - The decision was based on excitement for ZW251 and the ability to accelerate its clinical studies, while still maintaining momentum for ZW171 and ZW191 [58][60] Question: What are the gating factors for filing the IND for ZW1528? - The company is focused on completing IND enabling activities and expects to provide realistic guidance for filing in the second half of 2026 [115][116] Question: Can you share thoughts on multi-payload ADCs? - Management indicated that they are investigating additional payloads and consider the therapeutic rationale important for developing such molecules [120] Question: What is the desired target product profile for ZW251? - The company aims to demonstrate efficacy across a broad range of hepatocellular carcinoma models and believes in the importance of the target in their design [128][129]